IDF21-0454 Time-varying associations of long-term use of RASi use and all-site Cancers and mortality in type 2 diabetes (2002-2019)

Abstract

Background: Cancer has replaced cardiovascular disease (CVD) as the leading cause of death in many countries. Type 2 diabetes (T2D) is associated with increased risk of cancer. Renin-angiotensin system inhibitors (RASi) are prescribed for hypertension and organ-protection, but may have pluripotent, anti-cancer effects. Evidence for a link between RASi and cancer remains inconclusive and prior studies did not account for time-varying and cumulative treatment effects.